Evidence map›Paper›PMID 31180560›Full record

ArticleMolecular medicine reports2019

Novel de novo frameshift variant in the ASXL3 gene in a child with microcephaly and global developmental delay.

Marketa Wayhelova, Jan Oppelt, Jan Smetana, Eva Hladilkova, Hana Filkova, Eva Makaturova, Petra Nikolova, Rastislav Beharka, Renata Gaillyova, Petr Kuglik

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Additional Sex Combs-like Family Associated with Epigenetic Regulation.International journal of molecular sciences · 2024
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Novel mutation in theWorld journal of clinical cases · 2020
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Marketa WayhelovaInstitute of Experimental Biology, Faculty of Science, Masaryk University, 611 37 Brno, Czech Republic.
Jan OppeltCEITEC‑Central European Institute of Technology, Masaryk University, 625 00 Brno, Czech Republic.
Jan SmetanaInstitute of Experimental Biology, Faculty of Science, Masaryk University, 611 37 Brno, Czech Republic.
Eva HladilkovaDepartment of Medical Genetics, University Hospital Brno, 625 00 Brno, Czech Republic.
Hana FilkovaDepartment of Medical Genetics, University Hospital Brno, 625 00 Brno, Czech Republic.
Eva MakaturovaDepartment of Medical Genetics, University Hospital Brno, 625 00 Brno, Czech Republic.
Petra NikolovaDepartment of Medical Genetics, University Hospital Brno, 625 00 Brno, Czech Republic.
Rastislav BeharkaDepartment of Medical Genetics, University Hospital Brno, 625 00 Brno, Czech Republic.
Renata GaillyovaDepartment of Medical Genetics, University Hospital Brno, 625 00 Brno, Czech Republic.
Petr KuglikInstitute of Experimental Biology, Faculty of Science, Masaryk University, 611 37 Brno, Czech Republic.
University Hospital Brno · CZMasaryk University · CZCentral European Institute of Technology – Masaryk University · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

De novo sequence variants, including truncating and splicing variants, in the additional sex‑combs like 3 gene (ASXL3) have been described as the cause of Bainbridge‑Ropers syndrome (BRS). This pathology is characterized by delayed psychomotor development, severe intellectual disability, growth delay, hypotonia and facial dimorphism. The present study reports a case of a girl (born in 2013) with severe global developmental delay, central hypotonia, microcephaly and poor speech. The proband was examined using a multi‑step molecular diagnostics algorithm, including karyotype and array‑comparative genomic hybridization analysis, with negative results. Therefore, the proband and her unaffected parents were enrolled for a pilot study using targeted next‑generation sequencing technology (NGS) with gene panel ClearSeq Inherited DiseaseXT and subsequent validation by Sanger sequencing. A novel de novo heterozygous frameshift variant in the ASXL3 gene (c.3006delT, p.R1004Efs*21), predicted to result in a premature termination codon, was identified. In conclusion, the present study demonstrated that targeted NGS using a suitable, gene‑rich panel may provide a conclusive molecular genetics diagnosis in children with severe global developmental delays.

Indexed as

ChildDevelopmental DisabilitiesFemaleFrameshift MutationHumansMaleMicrocephalyMuscle HypotoniaPedigreePilot ProjectsRepressor ProteinsSpeech DisordersTranscription FactorsASXL3 protein, humanRepressor ProteinsTranscription Factors

Identifiers

PMID31180560
PMCPMC6579994
OpenAlexW2946997825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.